Scholarlink

Purpose <p>To evaluate the safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer (PROC).</p> Methods <p>We enrolled PROC patients who received intravenous nab-paclitaxel (260&#xa0;mg/m<sup>2</sup>), nedaplatin (80&#xa0;mg/m<sup>2</sup>), and bevacizumab (10&#xa0;mg/kg) every 3&#xa0;weeks between January 1, 2021, and October 1, 2025. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), CA125 response rate, objective response rate (ORR), duration of response (DOR), and safety.</p> Results <p>Twenty-seven patients were included (median age 57.8&#xa0;years; range: 35—78), 16 (59.3%) had received ≥ 3 prior chemotherapy lines; 40.7% and 59.3% had prior bevacizumab and PARP inhibitor exposure, respectively. After a median follow-up of 10&#xa0;months (range: 3–40), the median PFS was 7.0&#xa0;months (95% CI 5.8–8.2), with a 2-year OS rate of 57.3%. The CA125 response rate was 81.5%, with a median CA125 reduction of 70.2% (IQR 62.6–93.4), and 48.1% of patients achieved CA125 normalization. Prior chemotherapy lines, bevacizumab/PARP inhibitors exposure, and a shorter platinum-free interval did not alter the therapeutic efficacy (all <i>P</i> &gt; 0.05). Among 12 patients evaluable per RECIST v1.1 criteria, the ORR was 58.3%, the median DOR was 7.0&#xa0;months (95% CI 4.9–9.0), and the disease control rate was 100%. Grade 3–4 treatment-related adverse events occurred in 10 patients, mostly hematologic toxicities.</p> Conclusion <p>This chemotherapy regimen demonstrated satisfactory therapeutic efficacy and manageable toxicity in heavily pretreated PROC, suggesting its potential as a viable treatment alternative.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月27日

查看全文
  • Sijian Li,
  • Bingna Xian,
  • Lanyue Cui,
  • Linyu Wu,
  • Cheng Fang,
  • Fan Yang,
  • Jundong Li

摘要

Purpose

To evaluate the safety and efficacy of nab-paclitaxel combined with nedaplatin and bevacizumab in patients with platinum-resistant epithelial ovarian cancer (PROC).

Methods

We enrolled PROC patients who received intravenous nab-paclitaxel (260 mg/m2), nedaplatin (80 mg/m2), and bevacizumab (10 mg/kg) every 3 weeks between January 1, 2021, and October 1, 2025. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), CA125 response rate, objective response rate (ORR), duration of response (DOR), and safety.

Results

Twenty-seven patients were included (median age 57.8 years; range: 35—78), 16 (59.3%) had received ≥ 3 prior chemotherapy lines; 40.7% and 59.3% had prior bevacizumab and PARP inhibitor exposure, respectively. After a median follow-up of 10 months (range: 3–40), the median PFS was 7.0 months (95% CI 5.8–8.2), with a 2-year OS rate of 57.3%. The CA125 response rate was 81.5%, with a median CA125 reduction of 70.2% (IQR 62.6–93.4), and 48.1% of patients achieved CA125 normalization. Prior chemotherapy lines, bevacizumab/PARP inhibitors exposure, and a shorter platinum-free interval did not alter the therapeutic efficacy (all P > 0.05). Among 12 patients evaluable per RECIST v1.1 criteria, the ORR was 58.3%, the median DOR was 7.0 months (95% CI 4.9–9.0), and the disease control rate was 100%. Grade 3–4 treatment-related adverse events occurred in 10 patients, mostly hematologic toxicities.

Conclusion

This chemotherapy regimen demonstrated satisfactory therapeutic efficacy and manageable toxicity in heavily pretreated PROC, suggesting its potential as a viable treatment alternative.